Tags: Cancer | lung | cancer | treatment | approval alectinib | Alecensa

Lung Cancer Treatment Granted Accelerated Approval

Lung Cancer Treatment Granted Accelerated Approval
(Copyright AP)

Friday, 11 December 2015 03:50 PM


U.S. health regulators on Friday said they have granted accelerated approval to Roche Holding's drug for advanced lung cancer in patients with a specific genetic mutation.

The drug, alectinib, to be sold under the brand name Alecensa, was approved to treat patients with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate, treatment with Pfizer's Xalkori.

"Today's approval provides a new therapy for a group of patients who would have few treatment options once their disease no longer responds to treatment with Xalkori," Richard Pazdur, head of the Food and Drug Administration's Hematology and Oncology Products division, said in a statement.

Xalkori was seen as an advance in the field of personalized medicine as it was designed to treat only patients with the ALK genetic mutation, which account for about 4 percent of NSCLC patients. Pfizer is also developing a drug for ALK positive patients who have stopped responding to Xalkori.

The FDA's Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition based on early evidence of clinical benefit.

A confirmatory study is required to verify the benefit of Alecensa for it to gain full approval, the agency said.



© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
U.S. health regulators on Friday said they have granted accelerated approval to Roche Holding's drug for advanced lung cancer in patients with a specific genetic mutation. The drug, alectinib, to be sold under the brand name Alecensa, was approved to treat patients with...
lung, cancer, treatment, approval alectinib, Alecensa
207
2015-50-11
Friday, 11 December 2015 03:50 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved